Kanabo Group PLC

11 March 2022

Kanabo Group Plc

("Kanabo" or the "Company")

Investor Updates

Kanabo Group Plc (LSE:KNB), the pan-European medical cannabis Company focussing on the development and distribution of cannabis-derived products for medical patients and wellness CBD consumers, has posted their latest investor newsletter and investor presentation to their website.

The latest Company presentation can be viewed here;


The Company has also posted a recent webinar with Vox Markets where Kanabo CEO, Avihu Tamir and GP Service CEO, Atul Devani discuss the GP Services acquisition. The webinar can be viewed here;

Watch the Kanabo webinar hosted by Vox Markets - Vox Markets

The latest Kanabo Investor Newsletter discussing the significant progress made over recent months can be viewed here; https://www.kanabogroup.com/press/foreword-from-the-ceo-march-11-2002/

For further information, please visit http://www.kanabogroup.com/ or contact the following:

 Kanabo Group Plc 
 Avihu Tamir, CEO                     Via Vox Markets 
 Peterhouse Capital Ltd 
 Eran Zucker (Financial Adviser)      Tel: +44 (0)20 7469 
 Lucy Williams / Charles Goodfellow   Tel: +44 (0)20 7469 
  (Corporate Broker)                   0930 
 Vox Markets (Investor Relations) 
 Kat Perez                            KanaboGroup@voxmarkets.co.uk 

About Kanabo Group Plc

Kanabo Group Plc is creating a new standard in the medical cannabis industry to improve the well-being of millions of people around the world by providing a better alternative to the smoking of medicinal cannabis flowers. Kanabo, which was the first medicinal cannabis company to IPO on London Stock Exchange, has a focus on the distribution of cannabis-derived products for medical patients and non-THC products for CBD consumers. It has conducted extensive Research & Development to produce high-quality cannabis extract formulas, innovative medical-grade vaporizers, and various non-smoking consumption solutions. Kanabo sells a range of medical cannabis products and wellness CBD products in the Primary Markets, including its VapePod, which delivers a metered dose with every inhalation.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

March 11, 2022 06:23 ET (11:23 GMT)

Kanabo (LSE:KNB)
Gráfica de Acción Histórica
De May 2022 a Jun 2022 Haga Click aquí para más Gráficas Kanabo.
Kanabo (LSE:KNB)
Gráfica de Acción Histórica
De Jun 2021 a Jun 2022 Haga Click aquí para más Gráficas Kanabo.